| Name | Title | Contact Details |
|---|---|---|
Diana Rivenburgh |
Senior Vice President, People | Profile |
Uroplasty is a global medical company committed to offering transformative treatment options through specialty physicians. Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices. Uroplasty’s products include the Urgent® PC Neuromodulation System, a non-drug, non-surgical office-based treatment for Overactive Bladder and associated symptoms of urinary urgency, urinary frequency and urge incontinence. Urgent PC is an FDA-cleared system that delivers PTNS (Percutaneous Tibial Nerve Stimulation) and is also indicated for the treatment of fecal incontinence outside the US market. Uroplasty also offers Macroplastique®, an injectable urethral bulking agent for female stress urinary incontinence primarily due to intrinsic sphincter deficiency. Female SUI only in U.S.; male and female SUI outside the U.S. Uroplasty products are typically used when a patient’s treatment goals are not met after conservative and/or drug therapies. Providers and patients alike appreciate that Uroplasty products provide low-risk, effective alternatives to invasive surgery. And because these treatments can be delivered in an office or outpatient setting, the end result is that more patients are given the opportunity to transform their lives with successful treatment.
Health Hero Network, Inc. is a Palo Alto, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
At PanOptica, our aim is to develop new ocular therapies that help patients see their very best throughout their lives. Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient`s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully. Today, significant progress is being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.
BodyMedia is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Pittsburgh, PA. To find more information about BodyMedia, please visit www.bodymedia.com
At Blue Shield of California, we`re focused on fundamentally improving the ways in which members can access care and use their coverage. We`re investing in talented employees and new technologies to create an unrivaled member experience that elevates expectations and achieves our mission of making health care more accessible and affordable than ever. Today we are the third-largest health plan in the state and we`re dedicated to transforming the healthcare industry. Headquartered in San Francisco, with 18 additional offices across California, we`re proud to service over 4 million members and employ more than 6,000 people. We are an independent member of the Blue Shield Association. Blue Shield of California complies with applicable state laws and federal civil rights laws, and does not discriminate on the basis of race, color, national origin, ancestry, religion, sex, marital status, gender, gender identity, sexual orientation, age, or disability. Blue Shield of California cumple con las leyes estatales y las leyes federales de derechos civiles vigentes, y no discrimina por motivos de raza, color, país de origen, ascendencia, religión, sexo, estado civil, género, identidad de género, orientación sexual, edad ni discapacidad.